PHAXIAM Therapeutics
Florian Tavernier is an experienced laboratory researcher with a focus on cancer cell lines and enzyme mechanisms at ERYTECH Pharma since May 2017. Prior to this role, Florian worked at Sanofi Pasteur as a quality control technician specializing in virology, where responsibilities included planning and conducting biochemical and cell culture tests on viral vaccines. Florian's earlier experience includes working at SEDIAG as a cell culture technician, producing ELISA diagnostic kits and monoclonal antibodies, and a research internship at Inra, focusing on the biochemistry of olfactory metabolism. Florian holds a professional license in plant tissue culture and molecular biology and a DUT in biological engineering.
PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.